Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference on September 4, the Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 10. All presentations will be available via webcast on the company's website.
Cartesian Therapeutics (NASDAQ: RNAC), società biotecnologica in fase clinica specializzata in terapie cellulari per le malattie autoimmuni, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario a settembre 2025.
L'azienda interverrà al Cantor Global Healthcare Conference il 4 settembre, al Morgan Stanley Healthcare Conference il 9 settembre e all'H.C. Wainwright Global Investment Conference il 10 settembre. Tutte le presentazioni saranno disponibili in webcast sul sito web della società.
Cartesian Therapeutics (NASDAQ: RNAC), una biotecnológica en fase clínica centrada en terapias celulares para enfermedades autoinmunes, ha anunciado su participación en tres importantes conferencias para inversores del sector sanitario en septiembre de 2025.
La compañía participará en la Cantor Global Healthcare Conference el 4 de septiembre, en la Morgan Stanley Healthcare Conference el 9 de septiembre y en la H.C. Wainwright Global Investment Conference el 10 de septiembre. Todas las presentaciones estarán disponibles en webcast en la página web de la compañía.
Cartesian Therapeutics (NASDAQ: RNAC)는 자가면역 질환용 세포치료제에 주력하는 임상 단계의 생명공학 기업으로, 2025년 9월에 열리는 주요 헬스케어 투자자 컨퍼런스 3곳에 참가한다고 발표했습니다.
회사는 9월 4일 Cantor Global Healthcare Conference, 9월 9일 Morgan Stanley Healthcare Conference, 9월 10일 H.C. Wainwright Global Investment Conference에 참여합니다. 모든 발표는 회사 웹사이트를 통해 웹캐스트로 시청 가능합니다.
Cartesian Therapeutics (NASDAQ: RNAC), une société de biotechnologie en phase clinique spécialisée dans les thérapies cellulaires pour les maladies auto-immunes, a annoncé sa participation à trois grandes conférences pour investisseurs du secteur de la santé en septembre 2025.
La société interviendra à la Cantor Global Healthcare Conference le 4 septembre, à la Morgan Stanley Healthcare Conference le 9 septembre et à la H.C. Wainwright Global Investment Conference le 10 septembre. Toutes les présentations seront disponibles en webdiffusion sur le site internet de la société.
Cartesian Therapeutics (NASDAQ: RNAC), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit Schwerpunkt auf Zelltherapien für Autoimmunerkrankungen, hat seine Teilnahme an drei bedeutenden Healthcare-Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird an der Cantor Global Healthcare Conference am 4. September, der Morgan Stanley Healthcare Conference am 9. September und der H.C. Wainwright Global Investment Conference am 10. September teilnehmen. Alle Präsentationen werden via Webcast auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
- A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025
- A fireside chat at Morgan Stanley’s 23rd Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, September 9, 2025
- A presentation at the H.C. Wainwright 27th Annual Global Investment Conference at 8:30 a.m. ET on Wednesday, September 10, 2025
Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
When is Cartesian Therapeutics (RNAC) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access Cartesian Therapeutics' (RNAC) conference presentations?
What type of company is Cartesian Therapeutics (RNAC)?
Which investor conferences will Cartesian Therapeutics (RNAC) attend in September 2025?
